V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007461 | 10005332 | 1.54 | 76.6 | Curative (C) | 2015-04-10 | 2015-04-17 | Pazopanib | 02 | N | 10550165 | IPILIMUMAB |
| 10007462 | 10005333 | null | 95 | Palliative (P) | 2018-08-07 | 2018-08-26 | Cisplatin 100 + RT(H&N) 1 day | 02 | N | 10550166 | CAPECITABINE + CISPLATIN |
| 10007463 | 10005333 | null | null | Adjuvant (A) | 2018-11-01 | 2018-11-15 | TAC | 99 | N | 10550166 | CYCLOPHOSPHAMIDE |
| 10007464 | 10005334 | 1.6 | 69.5 | Palliative (P) | 2016-11-27 | 2016-11-27 | FEC + TRASTUZUMAB | N | N | 10550423 | CISPLATIN + PEMETREXED |
| 10007465 | 10005335 | 1.7 | null | Curative (C) | 2018-02-01 | 2018-02-08 | Methotrexate intrathecal | N | N | 10550478 | HYDROXYCARBAMIDE |
| 10007466 | 10005336 | 1.68 | 61.7 | Palliative (P) | null | 2017-03-02 | IRINOTECAN + MDG + PANITUMUMAB | N | N | 10550571 | ENZALUTAMIDE |
| 10007467 | 10005337 | 1.63 | 61.4 | Palliative (P) | 2018-04-28 | 2018-05-19 | AFATINIB | N | N | 10551030 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 10007468 | 10005338 | null | 77.9 | Palliative (P) | 2017-05-14 | 2017-06-05 | Chlorambucil | 02 | N | 10551288 | BORTEZOMIB + PANOBINOSTAT |
| 10007469 | 10005339 | 1.54 | 73.4 | Palliative (P) | 2018-01-10 | 2018-01-12 | CMF IV (28 day) | 2 | N | 10551288 | FEC + DOCETAXEL |
| 10007470 | 10007654 | null | 92.5 | Palliative (P) | 2018-03-20 | 2018-04-19 | Methotrexate High Dose (3g/m2) | N | N | 10551376 | ESHAP |
| 10007471 | 10007654 | 1.83 | 75.8 | Palliative (P) | 2017-06-10 | 2017-06-28 | Cape+Cisplatin+Trastuzumab Load | 02 | null | 10551376 | CETUXIMAB |
| 10007472 | 10005341 | 1.57 | 104 | Adjuvant (A) | 2018-06-30 | 2018-06-30 | Fluorouracil+Mitomycin+RT (Bladder) | 01 | N | 10551752 | BORTEZOMIB |
| 10007473 | 10007655 | 0 | 78.4 | Palliative (P) | 2017-02-28 | 2017-03-06 | MITOMYCIN | N | N | 10551778 | RUXOLITINIB |
| 10007474 | 10005345 | 0 | 87 | Curative (C) | 2016-01-23 | 2016-01-23 | TOPOTECAN | 02 | N | 10551912 | POMALIDOMIDE |
| 10007475 | 10005346 | 1.7 | 82 | Palliative (P) | 2016-01-05 | 2016-02-28 | IVAC | N | N | 10552239 | CETUXIMAB + OXALIPLATIN + MDG |
| 10007476 | 10007656 | 0 | 73.6 | Palliative (P) | 2018-02-13 | 2018-02-13 | Sorafenib | 01 | N | 10552352 | NINTEDANIB |
| 10007477 | 10005347 | 1.77 | 63.6 | Curative (C) | 2016-04-12 | 2016-04-14 | ECX | 2 | null | 10552475 | BORTEZOMIB |
| 10007478 | 10005347 | 1.62 | 59.75 | Adjuvant (A) | 2016-11-17 | 2016-11-17 | Cetuximab + FOLFIRI cycle 2 onwards | null | null | 10552475 | CYCLOPHOSPHAMIDE |
| 10007479 | 10005348 | 1.64 | 98 | Palliative (P) | 2017-11-26 | 2017-11-29 | Cisplatin | 2 | N | 10552934 | TOPOTECAN |
| 10007480 | 10005349 | 1.77 | 77.4 | Palliative (P) | 2015-11-24 | 2015-12-11 | Capecitabine + Cisplatin + RT | 2 | N | 10552953 | CHLORAMBUCIL + RITUXIMAB |
| 10007481 | 10005350 | 1.62 | 95.6 | Adjuvant (A) | 2015-05-24 | 2015-06-09 | CISPLATIN + VINORELBINE + RT | N | N | 10553132 | POMALIDOMIDE |
| 10007482 | 10005351 | 1.74 | 77.3 | Curative (C) | 2015-01-02 | 2015-01-23 | EOX | N | N | 10553784 | R CODOX-M/ R IVAC |
| 10007483 | 10005351 | 1.68 | 54.5 | Palliative (P) | 2015-12-28 | 2016-01-03 | Cyclophosphamide oral | N | N | 10553784 | CETUXIMAB + OXALIPLATIN + MDG |
| 10007484 | 10005353 | null | 66.05 | Disease modification (D) | 2017-04-06 | 2017-05-07 | CYCLOPHOSPHAMIDE + MITOXANTRONE + RITUXIMAB + VINCRISTINE | 02 | N | 10553903 | NIVOLUMAB |
| 10007485 | 10005353 | 1.71 | 104.7 | Disease modification (D) | 2016-03-06 | 2016-03-06 | EOX | 2 | Y | 10553903 | VENETOCLAX |
| 10007486 | 10005354 | 1.79 | 68.6 | Disease modification (D) | 2013-11-26 | 2014-04-25 | ECX | 99 | N | 10554411 | IRINOTECAN |
| 10007487 | 10007661 | 1.79 | 103 | Disease modification (D) | 2015-09-17 | 2016-01-10 | ECX | 2 | N | 10554499 | NIVOLUMAB |
| 10007488 | 10005355 | 1.57 | 52.6 | Disease modification (D) | 2017-01-12 | 2017-02-10 | Ixazomib + Lenalidomide | N | N | 10554676 | FEC + DOCETAXEL |
| 10007489 | 10007662 | 1.9 | 95.6 | Curative (C) | null | 2015-06-05 | ECX | 02 | N | 10554850 | BORTEZOMIB |
| 10007490 | 10007662 | 1.79 | 82.6 | Curative (C) | 2018-01-26 | 2018-01-26 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 10554850 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 10007491 | 10007662 | 1.68 | null | Adjuvant (A) | 2019-03-30 | 2019-04-02 | Cisplatin + Vinorelbine (PO) | null | N | 10554850 | CVD |
| 10007492 | 10005358 | null | 66.6 | Not known (9) | 2016-05-07 | 2016-06-04 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 10555236 | LIPOSOMAL DOXORUBICIN |
| 10007493 | 10007663 | 1.74 | 63.5 | Palliative (P) | null | 2017-02-27 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | N | 10555795 | TCX |
| 10007494 | 10005359 | 0 | 50.9 | Palliative (P) | null | 2018-06-09 | FEC 60 or 75 | N | N | 10555988 | CISPLATIN + FLUOROURACIL |
| 10007495 | 10005360 | null | 71.6 | Palliative (P) | 2018-10-24 | 2018-11-30 | Hydroxycarbamide | N | N | 10556056 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10007496 | 10007664 | 1.8 | 79.5 | Palliative (P) | null | 2017-10-24 | Hydroxycarbamide | N | N | 10556254 | CAPECITABINE + CARBOPLATIN |
| 10007497 | 10007664 | null | 70 | Curative (C) | 2017-06-30 | 2017-07-01 | CHLORAMBUCIL + RITUXIMAB | 2 | N | 10556254 | REMODL TRIAL |
| 10007498 | 10007664 | 1.53 | 49.5 | Adjuvant (A) | 2017-07-24 | 2017-09-05 | VEPEMB | 2 | Y | 10556254 | HYDROXYCARBAMIDE |
| 10007499 | 10005361 | 1.71 | 106.6 | Palliative (P) | 2016-05-19 | 2016-05-26 | Chlorambucil | N | Y | 10556484 | RIALTO TRIAL |
| 10007500 | 10005363 | 1.5 | 69.5 | Palliative (P) | 2015-05-05 | 2015-05-12 | PACLITAXEL + TRASTUZUMAB | 2 | N | 10556575 | CETUXIMAB + IRINOTECAN + MDG |
| 10007501 | 10007665 | 1.6 | null | Palliative (P) | 2016-01-14 | 2016-06-03 | Epirubicin | null | N | 10556710 | METHOTREXATE HIGH DOSE |
| 10007502 | 10005364 | null | null | Palliative (P) | 2019-01-11 | 2019-01-11 | TOPOTECAN | 02 | N | 10556888 | CAPECITABINE + CISPLATIN |
| 10007503 | 10007666 | null | null | Palliative (P) | 2017-05-31 | 2017-06-11 | DABRAFENIB | null | N | 10556888 | VINORELBINE |
| 10007504 | 10005365 | 1.64 | 60.7 | null | 2017-09-02 | 2017-09-07 | CISPLATIN + RT | N | Y | 10556922 | TOPOTECAN |
| 10007505 | 10005366 | 1.55 | null | Disease modification (D) | null | 2018-05-27 | Trifluridine + Tipiracil | null | N | 10557484 | CAPECITABINE + CARBOPLATIN + TRASTUZUMAB |
| 10007506 | 10005367 | 1.68 | 0 | Palliative (P) | 2014-04-09 | 2014-04-09 | GDP | 02 | null | 10557484 | CAPECITABINE + CARBOPLATIN |
| 10007507 | 10005368 | null | 93 | null | 2019-06-25 | 2019-06-26 | CETUXIMAB + IRINOTECAN + MDG | 2 | N | 10557618 | CETUXIMAB |
| 10007508 | 10005370 | 1.61 | 64.1 | null | 2019-01-11 | 2019-01-11 | CHLORAMBUCIL + OBINUTUZUMAB | 2 | N | 10558076 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 10007509 | 10005372 | 1.84 | 89.5 | Not known (9) | 2015-10-18 | 2016-01-12 | CHOEP | 2 | N | 10558140 | ENRICH TRIAL |
| 10007510 | 10005375 | 1.61 | null | Palliative (P) | 2017-09-03 | 2017-09-03 | Bortezomib +/- Dexamethasone | null | null | 10558140 | VINORELBINE |